Document is current
Any future updates will be listed below
-
Authors
Matsui, Sho
Yamamoto, Takeshi
Takabatake, Yoshitsugu
Takahashi, Atsushi
Namba-Hamano, Tomoko
Matsuda, Jun
Minami, Satoshi
Sakai, Shinsuke
Yonishi, Hiroaki
Nakamura, Jun
Kawai, Hideaki
Kubota, Takuya
Matsui, Isao
Yanagita, Motoko
Isaka, Yoshitaka
-
Funding
Funding for this research was provided by:
the G-7 Scholarship Foundation
Kanae Foundation for the Promotion of Medical Science
the Ichiro Kanehara Foundation
the Japan Diabetes Foundation
the Japan Diabetes Foundation/Costco Wholesale Japan Ltd.
Grant-in-Aid for Scientific Research from the Ministry of Education, Culture, Sports, Science and Technology of Japan (23K07671, 24K02467, 25K19490)
MSD Life Science Foundation, Public Interest Incorporated Foundation
Japan Diabetes Foundation/Nippon Boehringer Ingelheim Co., Ltd. & Eli Lilly Japan K.K.
the Osaka Kidney Bank
Uehara Memorial Foundation
- License Information
-
More Information
Article History
Received: 27 July 2025
Accepted: 6 October 2025
First Online: 28 November 2025
Acknowledgements
: We thank T. Matsusaka and F. Niimura (Tokai University School of Medicine) for providing the KAP-Cre mice, N. Mizushima (University of Tokyo) for the Atg5 F/F mice, T. Michigami (Osaka Medical Center and Research Institute) for the LRP2/MEGALIN antibody, and N. Horimoto (The University of Osaka) for technical assistance.
: All data are available from the authors upon reasonable request.
: This work was supported by Grants-in-Aid for Scientific Research from the Ministry of Education, Culture, Sports, Science and Technology of Japan (25K19490 to SM, 23K07671 to TY, and 24K02467 to YI), the Osaka Kidney Bank (to SM) and the Japan Diabetes Foundation (to SM), and by the Uehara Memorial Foundation, the G-7 Scholarship Foundation, the Kanae Foundation for the Promotion of Medical Science, the MSD Life Science Foundation, the Japan Diabetes Foundation/Nippon Boehringer Ingelheim Co. Ltd & Eli Lilly Japan K.K., the Japan Diabetes Foundation/Costco Wholesale Japan Ltd and the Ichiro Kanehara Foundation (to TY). This work was partially supported by Nippon Boehringer Ingelheim Co. Ltd and Eli Lilly Japan K.K. through a commissioned research agreement. Nippon Boehringer Ingelheim Co. Ltd and Eli Lilly Japan K.K. had no role in the design, analysis or interpretation of the results in this study.
: The authors declare that there are no relationships or activities that might bias, or be perceived to bias, their work.
: SMa and TY were responsible for study conception, investigation, data acquisition and analysis, and manuscript drafting and reviewing. YT was responsible for study conception and manuscript drafting and reviewing. AT, TNH, JM, SS, HY, JN, HK and TK contributed to data analysis and interpretation. YI, IM, YT, SMi and MY contributed to review and editing of the manuscript. All authors interpreted the data, critically revised the manuscript and approved the final version for submission. SMa, TY and YI are the guarantors of this work.
